Is Dr Agarwal's Eye overvalued or undervalued?

As of 16 October 2025, Dr Agarwal's Eye has moved from a fair to an expensive valuation grade. The company appears to be overvalued based on its current financial ratios, including a PE Ratio of 43.89, a Price to Book Value of 12.10, and an EV to EBITDA of 22.90. These figures suggest that the stock is trading at a significant premium compared to its earnings and book value. In comparison to its peers, Dr Agarwal's Eye has a higher PE ratio than Apollo Hospitals, which is valued attractively at 71.71, and Narayana Hrudaya, which is also expensive at 45.65. Furthermore, the company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 10.01% and 15.84%, respectively. However, the longer-term performance shows a decline of 11.91% year-to-date, indicating potential concerns about sustainability at its current valuation. Overall, Dr Agarwal's Eye is considered overvalued in the current market context.